about
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenibClinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaMelanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationImproved survival with vemurafenib in melanoma with BRAF V600E mutationGene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancerCombination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done YetSafety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyPharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.Impact of MET expression on outcome in BRAF(V600E/K) advanced melanoma.Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genesInhibition of Mutated, Activated BRAF in Metastatic MelanomaEfficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trialUV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell CarcinomasInhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signalingA novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent mannerCombined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaThe state of melanoma: challenges and opportunitiesAn open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma.Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell populationClinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KITClinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM studyPIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis.Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial.Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer.Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.Phenotype switching in melanoma: implications for progression and therapy.A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumorsBioinformatics pipelines for targeted resequencing and whole-exome sequencing of human and mouse genomes: a virtual appliance approach for instant deployment.Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanomaApplications of positron emission tomography in the development of molecular targeted cancer therapeutics.Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trialsPrognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase III trial.c-Myb is required for progenitor cell homeostasis in colonic crypts.
P50
Q24594790-9746EBF3-8A96-4F16-A29C-02C111675D9DQ24597152-D54D985A-708E-4057-8E80-42FE3B289FE1Q24629474-16B2BFF3-8C3B-4521-BB1F-E4DD0F190856Q24631953-D8E94011-3B9A-4F34-80A2-7E249EFD9DD1Q24652481-EE9D51CA-5022-4DA8-8D43-945EE0089FA9Q26799864-F557E117-8E32-4C7B-AAA9-0395BF5FDB76Q27276774-54BB1BD0-42F5-47C8-9163-0BCCA2975009Q27777363-E8E5B691-BE75-4E31-A7BB-83C6714EF89DQ27852389-5B58EEB9-630D-43FA-B069-0A4ADA3D6134Q27852814-E2FC6170-C57D-4BEE-9C95-CAA2B7B410FAQ27853076-9B5249FA-580C-4387-942D-05766239154DQ27853201-7AA6AFFE-6550-422D-B0BB-F400D5DF7B82Q27860458-0676F79C-1D48-4304-A3F2-FF9E0EEDEE45Q28268831-8AB7927B-97DF-45D6-A57B-206C8032F2EFQ28270523-3E63662B-9531-478B-9541-CEF24A5632F1Q28468631-C3D79096-2555-4812-BFDE-C7436FD9EE31Q28817145-10B72E94-76AB-45D8-9A55-B5F243385FDDQ29615443-E41FECD1-C4F8-4746-AAE1-D5C8149D1520Q30276971-771F1784-D133-42D4-BB5A-284F70AC69C4Q33375582-29139652-5CE1-4554-990D-F404D7B92D86Q33424674-4C1A7B0F-4D1F-4AB8-9468-689DD2728E00Q33648995-9F843358-D98D-4EFC-BC52-D89F0ED09A11Q33731216-4C480F95-99F0-445E-9439-CA007071CF7EQ33794917-C5864D7D-4AB5-4BDB-BBFD-DABE62A19332Q33830941-226F89A5-4047-49D2-B9F2-D5188D26034BQ33933172-0E2A0B78-CE16-44FE-A38E-4628879E8832Q33946905-64722439-F43F-434B-B8AB-0A70D871584AQ34193953-E0A164D6-1DFE-4AD7-BD1E-3EEED5DBDAE5Q34554628-00FAA322-701B-4032-BE0B-9D3B52B99D57Q34608584-C6F9EA76-D6E5-46C3-AE57-989B0CB11D7AQ34636081-BD7A406C-A474-4582-A256-B4911E388014Q34647109-668DD6CD-3C13-4BA1-827D-D5630CA02121Q35081779-F5DE59A4-0C48-41C3-AE51-EE73D50E23EBQ35116704-706E58C6-F4DB-4E2B-BA47-ABDA823E7205Q35154126-0D8D9E63-795A-44AC-86D4-1BD63857B1EAQ35176032-682DE8A5-BF06-46C6-8BEE-B9FBD9896DBAQ35537860-9CDBE4E4-91F2-42E9-86B8-F0D74FB1DCD8Q35645254-C16A37EE-391F-4513-91B9-7D76BBBF8E29Q35652920-E0D9DCFA-CCCE-48C1-AA3A-658FB101F846Q35676661-8FE2984B-4545-481B-AC73-540BB5324F94
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Grant McArthur
@ast
Grant McArthur
@en
Grant McArthur
@es
Grant McArthur
@nl
Grant McArthur
@sl
type
label
Grant McArthur
@ast
Grant McArthur
@en
Grant McArthur
@es
Grant McArthur
@nl
Grant McArthur
@sl
prefLabel
Grant McArthur
@ast
Grant McArthur
@en
Grant McArthur
@es
Grant McArthur
@nl
Grant McArthur
@sl
P106
P21
P31
P496
0000-0001-8908-6071